Phase 1 placebo-controlled trial of measles-vectored chikungunya vaccine (MV-CHIK) in 180 healthy adults across 6 cohorts: the 5x10^5 TCID50 dose was superior to 5x10^4, and longer dose intervals gave higher titres at high dose. Reactogenicity was common but brief.
RCTn = 180
Winokur et al. A Phase 1 Double-Blinded Trial to Evaluate Safety, Immunogenicity, and Dosing of Measles-Vectored Chikungunya Virus Vaccine (MV-CHIK) in Healthy Adults